Evidence map›Paper›PMID 28280276›Full record

ArticleLeukemia2017

Regulation of PI3K signaling in T-cell acute lymphoblastic leukemia: a novel PTEN/Ikaros/miR-26b mechanism reveals a critical targetable role for PIK3CD.

T Yuan, Y Yang, J Chen, W Li, W Li, Q Zhang, Y Mi, R S Goswami, J Q You, D Lin and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 62 citations in OpenAlex.

  1. TET1 deficiency amplifies macrophage inflammatory signaling associated with Crohn's disease.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. PI3K Targeting in Non-solid Cancer.Current topics in microbiology and immunology · 2022
    Review
  16. Review
  17. A Review of Phosphocreatine 3 Kinase δ Subtype (PI3Kδ) and Its Inhibitors in Malignancy.Medical science monitor : international medical journal of experimental and clinical research · 2021
    Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 6 institutions in 3 countries.

T YuanDepartment of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Y YangDepartment of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
J ChenDepartment of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
W LiDepartment of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
W LiDepartment of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Q ZhangDepartment of Leukemia, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
Y MiDepartment of Leukemia, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
R S GoswamiDepartment of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
J Q YouDepartment of Molecular and Cellular Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
D LinDepartment of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
M D QianDepartment of Experimental Therapeutics and Center for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
S CalinDepartment of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Y LiangDepartment of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
R N MirandaDepartment of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
G A CalinDepartment of Experimental Therapeutics and Center for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
X ZhouDepartment of Pathology, Shanghai Cancer Center, Fudan University, Shanghai, China.
L MaDepartment of Experimental Radiation Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
P A Zweidler-McKayDivision of Pediatric, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
B LiuDepartment of Genetics, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
A P WengDepartment of Pathology and Laboratory Medicine, the University of British Columbia, Vancouver, BC, Canada.
L J MedeirosDepartment of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Y ZhangDepartment of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
M J YouDepartment of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
The University of Texas MD Anderson Cancer Center · USInstitute of Hematology & Blood Diseases Hospital · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNFudan University Shanghai Cancer Center · CNShaoxing University · CNUniversity of British Columbia · CA

Funding

University of Texas M.D. Anderson Cancer SPORE-LeukemiaP50CA100632 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI REZVANI, KATY · 2003 to 2023
$43.7M
Regulation of metastasis and epithelial-mesenchymal transition by microRNAsR01CA166051 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MA, LI · 2012 to 2023
$3.4M
Genetic Epidemiology of non-Hodgkin LymphomaR01CA200703 · NCI · MAYO CLINIC ROCHESTER · PI CERHAN, JAMES R · 2016 to 2020
$3.3M
Epithelial-mesenchymal transition regulators in radioresistance and DNA repairR01CA181029 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MA, LI · 2014 to 2018
$1.7M
CHARACTERIZATION AND TARGETED THERAPY OF T-ALL DEFICIENT FOR PTEN AND INK4A/ARFR01CA164346 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI YOU, M. JAMES · 2012 to 2015
$1.2M
NCI NIH HHS P50 CA100632NCI NIH HHS R01 CA164346NCI NIH HHS R01 CA181029NCI NIH HHS R01 CA200703
6 · The paper itself

Abstract

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy, and T-ALL patients are prone to early disease relapse and suffer from poor outcomes. The PTEN, PI3K/AKT and Notch pathways are frequently altered in T-ALL. PTEN is a tumor suppressor that inactivates the PI3K pathway. We profiled miRNAs in Pten-deficient mouse T-ALL and identified miR-26b as a potentially dysregulated gene. We validated decreased expression levels of miR-26b in mouse and human T-ALL cells. In addition, expression of exogenous miR-26b reduced proliferation and promoted apoptosis of T-ALL cells in vitro, and hindered progression of T-ALL in vivo. Furthermore, miR-26b inhibited the PI3K/AKT pathway by directly targeting PIK3CD, the gene encoding PI3Kδ, in human T-ALL cell lines. ShRNA for PIK3CD and CAL-101, a PIK3CD inhibitor, reduced the growth and increased apoptosis of T-ALL cells. Finally, we showed that PTEN induced miR-26b expression by regulating the differential expression of Ikaros isoforms that are transcriptional regulators of miR-26b. These results suggest that miR-26b functions as a tumor suppressor in the development of T-ALL. Further characterization of targets and regulators of miR-26b may be promising for the development of novel therapies.

Indexed as

Signal TransductionAdolescentAdultAgedAnimalsCell Line, TumorClass I Phosphatidylinositol 3-KinasesHumansIkaros Transcription FactorMiceMice, Inbred NODMice, SCIDMicroRNAsMiddle AgedPrecursor T-Cell Lymphoblastic Leukemia-LymphomaProto-Oncogene Proteins c-aktClass I Phosphatidylinositol 3-KinasesIkaros Transcription FactorIKZF1 protein, humanMicroRNAsMIRN26 microRNA, humanPIK3CD protein, humanProto-Oncogene Proteins c-aktPTEN PhosphohydrolasePTEN protein, human

Identifiers

PMID28280276
PMCPMC5986278
OpenAlexW2594926959

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.